非肝硬化肝癌相关的血清学生物标志物:在临床诊断及预后中的应用前景  

Serological Biomarkers Related to Non-Cirrhotic Hepatocellular Carcinoma: Promising Applications in Clinical Diagnosis and Prognosis

作　　者：刘进玲 崔鲂[1] 

机构地区：[1]重庆医科大学附属第一医院检验医学科,重庆

出　　处：《临床医学进展》2025年第2期142-149,共8页Advances in Clinical Medicine

摘　　要：肝细胞癌是一种高度恶性的肿瘤,目前肝细胞癌患者的死亡率排名在所有癌症中占第三位。尤其在非肝硬化背景下,其早期诊断和预后评估更具挑战性。随着非肝硬化肝癌患病率的增加,早期诊断对于全面治疗具有重要意义。早期诊断可以提高患者的生存率和治疗成功率。因此,对于非肝硬化肝癌患者,识别和监测病因和风险因素对于早期诊断和治疗至关重要。本文综述了非肝硬化肝癌的临床特征,并重点讨论了非肝硬化肝癌患者的血清学标志物及其组合的应用价值,旨在为肝癌患者的早期诊断和预后判断提供参考。Hepatocellular carcinoma (HCC) is a highly malignant tumor, and the mortality rate of HCC patients currently ranks third out of all cancers. Especially in the non-cirrhotic setting, its early diagnosis and prognosis evaluation are more challenging. With the increasing prevalence of non-cirrhotic HCC, early diagnosis is important for comprehensive treatment. Early diagnosis can improve patient survival rates and treatment success rates. Therefore, identification and monitoring of etiology and risk factors are crucial for early diagnosis and treatment. This review summarizes the clinical features of non-cirrhotic HCC and focuses on the application value of serological markers and their combinations in non-cirrhotic HCC patients, aiming to provide reference for early diagnosis and prognosis of HCC patients.

关 键 词：非肝硬化肝癌 血清标志物 诊断 预后 

分 类 号：R73[医药卫生—肿瘤]